Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide safety/tolerability pilot in chromosome 5 abnormal AML or high-risk MDS
ISRCTN58492795Phase 2Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Jan 2009
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of lenalidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoints: Early death rate, Platelet recovery and survival by day 42 after chemotherapy and 1 more. Started Jan 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN58492795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN58492795.